Differentiation, No. (%)

<0.01

High

6 (1.9%)

1 (0.3%)

Middle

118 (37.3%)

107 (27.5%)

Lox

173 (54.7%)

248 (63.8%)

Other

19 (6.0%)

33 (8.5%)

Organizationtype, No. (%)

0.04

Adenocarcinoma

277 (87.7%)

318 (81.7%)

Other

39 (12.3%)

71 (18.3%)

Borrmann, No. (%)

<0.01

I

46 (14.6%)

23 (5.9%)

II

42 (13.3%)

19 (4.9%)

III

233 (70.6%)

323 (83.0%)

IV

5 (1.6%)

24 (6.2%)

Size No. (%), cm

<0.01

≤4

144 (45.6%)

76 (19.5%)

>4

172 (54.4%)

313 (80.5%)

T-Stage, No. (%)

<0.01

1

61 (19.3%)

11 (2.8%)

2

80 (25.3%)

44 (11.3%)

3

88 (27.8%)

134 (34.4%)

4a

83 (26.3%)

129 (33.2%)

4b

4 (1.3%)

71 (18.3%)

N-Stage No. (%)

<0.01

0

199 (63.0%)

86 (22.1%)

1

41 (13.0%)

62 (15.9%)

2

49 (15.5%)

97 (24.9%)

3a

24 (7.6%)

106 (27.2%)

3b

3 (0.9%)

38 (9.8%)

LODDS, No. (%)

<0.01

LODDS1

216 (68.4%)

108 (27.8%)

LODDS2

87 (27.5%)

179 (46.0%)

LODDS3

13 (4.1%)

102 (26.2%)

Chemotherapy No. (%)

<0.01

None

3 (0.9%)

70 (18.0%)

1~5 times

170 (53.8%)

278 (71.5%)

≥6 times

143 (45.3%)

41 (10.5%)